相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis
Avivit Cahn et al.
DIABETES OBESITY & METABOLISM (2019)
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
Devin Abrahami et al.
DIABETES CARE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology
Krzysztof Ozieranski et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis
Maarten A. de Jong et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology
Wilfried Mullens et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
Oriol Iborra-Egea et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Eduardo Flores et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors
Juan Tamargo et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
Christopher S. Wilcox et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome
Vojtech Melenovsky et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2018)
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study
Jenny E. Blau et al.
JCI INSIGHT (2018)
Assessing the left main stem in the cardiac catheterization laboratory. What is significant? Function, imaging or both?
George Kassimis et al.
CARDIOVASCULAR REVASCULARIZATION MEDICINE (2018)
SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms
T. D. Filippatos et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of acute hyperinsulinemia on magnesium homeostasis in humans
Li Hao Richie Xu et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease
Lauren B. Cooper et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
Richard E. Gilbert et al.
DIABETES THERAPY (2017)
Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
Richard E. Gilbert et al.
DIABETES THERAPY (2017)
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
Girish N. Nadkarni et al.
DIABETES CARE (2017)
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
Milton Packer
CIRCULATION (2017)
Hypomagnesemia in Type 2 Diabetes: A Vicious Circle?
Lisanne M. M. Gommers et al.
DIABETES (2016)
Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure
Dirk J. van Veldhuisen et al.
EUROPEAN HEART JOURNAL (2016)
FGF23 Regulates Bone Mineralization in a 1,25(OH) D-2(3) and Klotho-Independent Manner
Sathish Kumar Murali et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice
Kathryn M. Thrailkill et al.
BONE (2016)
Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure
Pierpaolo Pellicori et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development
Harmen G. Booij et al.
CARDIOVASCULAR RESEARCH (2016)
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
A. J. Scheen
DIABETES & METABOLISM (2016)
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
H. L. Tang et al.
DIABETES OBESITY & METABOLISM (2016)
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
Huilin Tang et al.
DIABETOLOGIA (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Linda A. Gallo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
The kidney in heart failure: an update
Kevin Damman et al.
EUROPEAN HEART JOURNAL (2015)
Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications
Caterina Urso et al.
HEART FAILURE REVIEWS (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Possible adverse effects of SGLT2 inhibitors on bone
Simeon I. Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Renal Control of Calcium, Phosphate, and Magnesium Homeostasis
Judith Blaine et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy
Anne-Roos S. Frenay et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
Matthew R. Weir et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Cardiac and Renal Fibrosis in Chronic Cardiorenal Syndromes
Aneley Hundae et al.
NEPHRON CLINICAL PRACTICE (2014)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
The role of the kidney in heart failure
Marco Metra et al.
EUROPEAN HEART JOURNAL (2012)
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice
Faiez Zannad et al.
EUROPEAN HEART JOURNAL (2012)
A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function
Steef J. Sinkeler et al.
HEART FAILURE REVIEWS (2012)
Target organ cross talk in cardiorenal syndrome: animal models
Lennart G. Bongartz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2012)
Magnesium basics
Wilhelm Jahnen-Dechent et al.
CLINICAL KIDNEY JOURNAL (2012)
Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure
Meimei Yin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
Calcium and Phosphate: A Duet of Ions Playing for Bone Health
Jean-Philippe Bonjour
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2011)
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Carol Kilkenny et al.
PLOS BIOLOGY (2010)
Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats
Willemijn A. K. M. Windt et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis
T Shimada et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy
SS Gottlieb et al.
CIRCULATION (2002)
分享论文
